Physician profile
Dwight William Sievert
NPI 1841388022
$21,595.70
in general payments reported to CMS, 2019-2025
37 companies · $2,850 in 2025
The $2,850 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,678 · 2020: $2,132 · 2021: $3,341 · 2022: $2,499 · 2023: $3,177 · 2024: $3,919 · 2025: $2,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,761 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,761.10 |
| Education | $184.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,756.63 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $2,277.69 | 2021-2025 | Vraylar |
| Lundbeck LLC | $1,937.45 | 2019-2025 | Rexulti, Brintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,694.20 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,657.41 | 2019-2024 | Trintellix |
| Alkermes, INC. | $1,545.08 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,376.98 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $1,340.25 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $903.89 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $842.06 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $760.87 | 2019-2022 | |
| Axsome Therapeutics, INC. | $695.12 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $586.22 | 2019-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $512.96 | 2019-2025 | Ingrezza |
| Corium, LLC | $390.02 | 2022-2024 | Azstarys |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $337.25 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $220.71 | 2019 | |
| Avanir Pharmaceuticals, INC. | $206.27 | 2019-2021 | |
| Tris Pharma INC | $201.34 | 2019-2025 | Dyanavel Xr |
| Indivior INC. | $183.34 | 2019-2024 | Perseris, Sublocade |
| Supernus Pharmaceuticals, INC. | $177.34 | 2022-2025 | Qelbree, Qelbree |
| Eisai INC. | $145.42 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $137.61 | 2019-2021 | |
| Alfasigma USA, INC. | $87.90 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $86.63 | 2025 | Jornay Pm |
| Neuronetics, INC. | $84.40 | 2019-2023 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $81.12 | 2022-2023 | Quviviq |
| Revance Therapeutics, INC. | $77.86 | 2024 | Daxxify |
| Sage Therapeutics, LLC | $60.96 | 2024-2025 | Zurzuvae |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $59.08 | 2022 | |
| Almatica Pharma LLC | $38.29 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $30.47 | 2019-2023 | Belsomra |
| Tempus Ai, INC | $29.42 | 2024 | |
| Arbor Pharmaceuticals, INC. | $27.76 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $20.49 | 2024 | Horizant |
| Owp Pharmaceuticals, INC. | $13.28 | 2023 | Subvenite, Lamotrigine |
| Mdd US Operations, LLC | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Sievert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.